The positive and consistent findings in both CFTR biomarkers and clinical outcome measures from the Phase II study of ivacaftor in G551D-CF patients provided a unique opportunity to determine the optimal measures for quantifying CFTR activity and inform future decisions in NPD analysis. This evidence concerns the gene CFTR and cystic fibrosis.